Browse the evidence

A tendency toward a greater increase in fat-free mass (FFM) was observed in the OC group (3.7 ± 3.8%) compared to nonusers (2.7 ± 3.5%), with p = 0.08.

There may be a slight advantage in fat-free mass gain for OC users, warranting further investigation.

Strength gains are stimulated through a sequence of events including maximal mental effort and neural activation.

Emphasize mental effort and neural activation in training programs to enhance strength gains.

The intake of dairy appears to have a protective effect on some cardiovascular risk factors, or it is not worse than other SFA sources.

Incorporating dairy may be beneficial for cardiovascular health compared to other saturated fats.

Dairy products seem to present a different effect on cardiometabolic risk factors than other fat sources.

Understanding the unique effects of dairy can inform dietary recommendations regarding fat sources.

The study evaluated three test diets differing in carbohydrate-to-fat ratio during weight-loss maintenance over 20 weeks.

Dietary composition may play a significant role in maintaining weight loss.

The primary outcome measured was total energy expenditure using doubly-labeled water methodology.

Understanding total energy expenditure can help in designing effective weight maintenance strategies.

Secondary outcomes included resting energy expenditure, physical activity, and chronic disease risk factors.

Monitoring these secondary outcomes can provide insights into the effectiveness of dietary interventions.

Once semaglutide is stopped, people regain most of their pretreatment weight.

Practitioners should inform patients about the potential for weight regain after stopping treatment.

Dietary intake of trans fatty acids, palmitic acid, stearic acid, and saturated fatty acids from meat and unprocessed meat was modestly associated with a higher risk of coronary events.

Reducing intake of certain fatty acids may be beneficial for lowering coronary event risk.

Bariatric surgery resulted in an overall 25.8% weight reduction, outperforming lifestyle and pharmacotherapy interventions.

Bariatric surgery may be the most effective intervention for significant weight loss in obese individuals.

GLP-1 receptor agonists and dual receptor agonists effectively counteract hyperglycemia and obesity.

These medications may be prioritized in treatment plans for T2D patients with obesity.

Higher carbohydrate intake is associated with an increased risk of stroke (HR=1.13, 95% CI: 1.01, 1.27).

Higher carbohydrate consumption may elevate stroke risk, warranting dietary adjustments.

Unimolecular GLP-1/GCG dual agonist and GLP-1/GIP/GCG triple agonist may offer superior weight loss efficacy over GLP-1 agonist.

Practitioners should consider these new agonists for potentially better weight loss outcomes.

A high body mass index is one of the strongest risk factors for new-onset Chronic Kidney Disease.

Monitoring BMI can be crucial for preventing Chronic Kidney Disease.

Obesity has been shown to be a risk factor for nephrolithiasis and kidney cancer.

Addressing obesity may reduce the risk of kidney stones and cancer.

Food is Medicine (FIM) interventions link food security, nutrition security, health, and health equity integrated into health care delivery.

Practitioners should consider integrating FIM interventions into health care to address food and nutrition security.

The rate of hospitalisations for stable angina pectoris (SAP) was lower by two-thirds after bariatric surgery in obese adults.

Bariatric surgery may significantly reduce hospitalisation rates for SAP in obese patients.

Recent patents emphasize the development of GLP-1 receptor agonists (GLP-1RAs) for oral delivery and improved weight reduction effects.

Practitioners should consider the potential of new GLP-1RAs that are orally administered and may enhance weight loss.

Subjects reported significantly greater perceptions of grip security, power, and technical competency at submaximal but not maximal loads.

Improved grip perceptions can enhance training effectiveness at submaximal loads.

GLP-1 receptor agonists demonstrated a mean systolic BP reduction of -3.37 mmHg and a mean diastolic BP reduction of -1.05 mmHg compared with placebo.

GLP-1 receptor agonists can be considered for managing blood pressure in overweight or obese patients.

The BP reduction effect of GLP-1 RAs was consistent across subgroups for diabetic status, formulation, follow-up duration, and route of administration.

GLP-1 receptor agonists can be effectively used across different patient subgroups for BP management.

Low intracellular ATP levels lead to carbohydrate-dependent hunger and impaired satiety.

Recognizing the link between ATP levels and hunger can aid in obesity treatment strategies.

There is no one-size-fits-all approach to dietary recommendations for the management and treatment of chronic diseases such as obesity.

Practitioners should consider individualized dietary recommendations rather than a standard approach.

There were no statistical differences in SMM and total strength improvements between the narrow and wide repetition zones.

Both repetition zones are equally effective for muscle and strength gains in older women.